Literature DB >> 9030577

The use of fluorescent probes to characterize conformational changes in the interaction between vitronectin and plasminogen activator inhibitor-1.

A Gibson1, K Baburaj, D E Day, I Verhamme, J D Shore, C B Peterson.   

Abstract

Plasminogen activator inhibitor-1 (PAI-1), the primary inhibitor of tissue-type plasminogen activator and urokinase, is known to convert readily to a latent form by insertion of the reactive center loop into a central beta-sheet. Interaction with vitronectin stabilizes PAI-1 and decreases the rate of conversion to the latent form, but conformational effects of vitronectin on the reactive center loop of PAI-1 have not been documented. Mutant forms of PAI-1 were designed with a cysteine substitution at either position P1' or P9 of the reactive center loop. Labeling of the unique cysteine with a sulfhydryl-reactive fluorophore provides a probe that is sensitive to vitronectin binding. Results indicate that the scissile P1-P1' bond of PAI-1 is more solvent exposed upon interaction with vitronectin, whereas the N-terminal portion of the reactive loop does not experience a significant change in its environment. These results were complemented by labeling vitronectin with an arginine-specific coumarin probe which compromises heparin binding but does not interfere with PAI-1 binding to the protein. Dissociation constants of approximately 100 nM are calculated for the vitronectin/PAI-1 interaction from titrations using both fluorescent probes. Furthermore, experiments in which PAI-1 failed to compete with heparin for binding to vitronectin argue for separate binding sites for the two ligands on vitronectin.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9030577     DOI: 10.1074/jbc.272.8.5112

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Formation and reversible dissociation of coiled coil of peptide to the C-terminus of the HSV B5 protein: a time-resolved spectroscopic analysis.

Authors:  Ordel J Brown; Santiago A Lopez; A Oveta Fuller; Theodore Goodson
Journal:  Biophys J       Date:  2007-05-11       Impact factor: 4.033

2.  Validation of the vitronectin knockout mouse as a model for studying myocardial infarction: Vitronectin appears to influence left ventricular remodelling following myocardial infarction.

Authors:  Gordon E Pate; Hubert P Walinski; Lubos Bohunek; Thomas J Podor
Journal:  Exp Clin Cardiol       Date:  2013

3.  Vitronectin binds to the gonococcal adhesin OpaA through a glycosaminoglycan molecular bridge.

Authors:  T D Duensing; J P Putten
Journal:  Biochem J       Date:  1998-08-15       Impact factor: 3.857

4.  A deletion mutant of vitronectin lacking the somatomedin B domain exhibits residual plasminogen activator inhibitor-1-binding activity.

Authors:  Christine R Schar; Grant E Blouse; Kenneth H Minor; Cynthia B Peterson
Journal:  J Biol Chem       Date:  2008-01-03       Impact factor: 5.157

5.  Characterization of a site on PAI-1 that binds to vitronectin outside of the somatomedin B domain.

Authors:  Christine R Schar; Jan K Jensen; Anni Christensen; Grant E Blouse; Peter A Andreasen; Cynthia B Peterson
Journal:  J Biol Chem       Date:  2008-07-24       Impact factor: 5.157

6.  Single fluorescence probes along the reactive center loop reveal site-specific changes during the latency transition of PAI-1.

Authors:  Tihami Qureshi; Cynthia B Peterson
Journal:  Protein Sci       Date:  2015-11-25       Impact factor: 6.725

7.  Distinct encounter complexes of PAI-1 with plasminogen activators and vitronectin revealed by changes in the conformation and dynamics of the reactive center loop.

Authors:  Tihami Qureshi; Sumit Goswami; Carlee S McClintock; Matthew T Ramsey; Cynthia B Peterson
Journal:  Protein Sci       Date:  2015-12-02       Impact factor: 6.725

Review 8.  PAI-1, the Plasminogen System, and Skeletal Muscle.

Authors:  Fasih Ahmad Rahman; Matthew Paul Krause
Journal:  Int J Mol Sci       Date:  2020-09-25       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.